TITLE 77: PUBLIC HEALTH
CHAPTER I: DEPARTMENT OF PUBLIC HEALTH
SUBCHAPTER k: COMMUNICABLE DISEASE CONTROL AND IMMUNIZATIONS
PART 690 CONTROL OF COMMUNICABLE DISEASES CODE
SECTION 690.361 CORONAVIRUS, NOVEL, INCLUDING CORONAVIRUS DISEASE 19 (COVID-19), SEVERE ACUTE RESPIRATORY SYNDROME (SARS), AND MIDDLE EASTERN RESPIRATORY SYNDROME (MERS) (REPORTABLE BY TELEPHONE IMMEDIATELY (WITHIN 3 HOURS) UPON INITIAL CLINICAL SUSPICION OF THE DISEASE)


 

Section 690.361  Coronavirus, Novel, including Coronavirus Disease 19 (COVID-19), Severe Acute Respiratory Syndrome (SARS), and Middle Eastern Respiratory Syndrome (MERS) (Reportable by telephone immediately (within 3 hours) upon initial clinical suspicion of the disease)

 

a)         Control of Case.

 

1)         All cases, including suspect cases, should be isolated at home or alternative setting for housing in accordance with Subpart I.

 

2)         Standard Precautions, Contact Precautions, Droplet Precautions including eye protection, and Airborne Infection Isolation Precautions shall be followed for cases or suspect cases in a health care facility. 

 

3)         When a case or suspected case is isolated in the home or in any other non-hospital setting, isolation procedures shall comply with Section 690.20(a)(4).

 

4)         Cleaning and disinfection procedures shall comply with the guidelines referenced in Section 690.1010(a)(4).

 

b)         Control of Contacts. 

 

1)         Contacts of cases shall be placed under surveillance, with close observation for fever and COVID-like respiratory symptoms in consultation with the Department or local health authority on public health management of contacts.  Observation and monitoring procedures shall comply with Section 690.20(a)(4).

 

2)         Close contacts of cases may be quarantined.  Quarantine procedures shall comply with Subpart I and Section 690.20(a)(4).

 

c)         Laboratory Reporting. 

 

1)         Laboratories and other facilities performing lab services that provide tests for screening, diagnosis, or monitoring of coronavirus disease shall report all laboratory results, including positive, negative, and indeterminate results for coronavirus tests, including, but not limited to, all molecular, antigen, and serological tests, including rapid tests, to the Department via the Department's electronic lab reporting (ELR) system in a manner and on a schedule prescribed by the Department.  Laboratories unable to submit results to the Department via the Department's ELR shall contact the Department for instructions on how to submit results. 

 

2)         Positive results shall be reported to the Department immediately, within 3 hours.

 

3)         In addition to the ELR submission required in subsection 361(c)(1), laboratories shall submit all test results and corresponding data, including, but not limited to, the test type, specimen source and patient demographic data, including but not limited to race, ethnicity, sex and address information, to the Department via the Illinois National Electronic Disease Surveillance System (I-NEDSS) within 24 hours after testing until the file is ready for production.

 

4)         Laboratories and other facilities performing lab services shall instruct their clients that patient demographic information must be submitted with the order request. 

 

5)         Laboratories shall only submit results for tests they have performed. Laboratories shall not submit results on referred specimens.

 

6)         If deemed necessary by the Department or local health authority, laboratories shall forward clinical specimens to the Department's laboratory for further testing.

 

(Source:  Added at 44 Ill. Reg. 20145, effective December 9, 2020)